Meet Nicola
Meet Nicola who is living with the disease of Obesity and learn how you can identify patients in your practice who could benefit from Mysimba 1
Age: 42.
BMI: 34kg/m2.
Job: Nurse.
This patient is fictious
History
Nicola recognises that her eating habits and cravings for food are tied to her emotions.
Nicola would prefer an oral to an injectable obesity treatment.
She is also concerned about the cost of obesity medicines.
Why Prescribe Mysimba®?
Guidelines suggest the use of Mysimba 1st line for patients with obesity and cravings2*
Mysimba is an oral tablet which supports long-term weight management in patients with obesity.1
Nicola will know at 16 weeks if Mysimba is working for her.1
Patients like Nicola want to lose weight, but they experience emotional eating and cravings when they are stressed throughout the day. Adding Mysimba (a weight loss medication designed to reduce hunger and control cravings) to the diet and exercise, may help them to lose weight and keep it off 1,3,4,*
References
- Mysimba 8 mg/90 mg prolonged-release tablets Summary of Product Characteristics available on medicines.ie or www.ema.europa.eu .
- Le Roux et al, Algorithm: Choice of Obesity Pharmacotherapy, Chapter: Pharmacotherapy in Obesity Management, ASOI Clinical Practice Guideline for the Management of Obesity in Adults in Ireland, p15.
- Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196. doi:10.1038/ijo.2015.59
- Acosta A, Camilleri M, Dayyeh BA, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120
* The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions
IE-MYS-211(1), MYS-0454-001 01/26 DOP: January 2026
The information on this website is intended for Healthcare Professionals who reside in Ireland and Malta only.
Healthcare professionals who reside in Ireland are asked to report any suspected adverse events to: HPRA Pharmacovigilance via www.hpra.ie;
Adverse events should also be reported to Orexigen: +353 1800 849 099 or Currax.Ml@primevigilance.com.
Healthcare professionals who reside in Malta are asked to report any suspected adverse events to: the Malta Medicines Authority via http://medicinesauthority.gov.mt/adrportal or Vivian Corporation Ltd. via pv@viviancorp.com.
Adverse events should also be reported to Orexigen: +356 800 62176 or Currax.Ml@primevigilance.com.